6LUA Stock Overview
NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
NVN Liquidation, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.001 |
| 52 Week High | US$1.97 |
| 52 Week Low | US$0.001 |
| Beta | -0.24 |
| 11 Month Change | 0% |
| 3 Month Change | -97.78% |
| 1 Year Change | -99.92% |
| 33 Year Change | -99.98% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6LUA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -1.8% |
| 1Y | -99.9% | -12.7% | 13.2% |
Return vs Industry: 6LUA underperformed the German Pharmaceuticals industry which returned -26.5% over the past year.
Return vs Market: 6LUA underperformed the German Market which returned 9.5% over the past year.
Price Volatility
| 6LUA volatility | |
|---|---|
| 6LUA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6LUA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 6LUA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 90 | n/a | www.novan.com |
NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2.
NVN Liquidation, Inc. Fundamentals Summary
| 6LUA fundamental statistics | |
|---|---|
| Market cap | €5.14k |
| Earnings (TTM) | -€29.40m |
| Revenue (TTM) | €22.86m |
0.0x
P/S Ratio0.0x
P/E RatioIs 6LUA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6LUA income statement (TTM) | |
|---|---|
| Revenue | US$24.92m |
| Cost of Revenue | US$24.45m |
| Gross Profit | US$473.00k |
| Other Expenses | US$32.52m |
| Earnings | -US$32.05m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | 1.90% |
| Net Profit Margin | -128.61% |
| Debt/Equity Ratio | -1,164.1% |
How did 6LUA perform over the long term?
See historical performance and comparison